Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GZMB | P10144 | 3/20 | 0.44 |
| ▸ | CALCRL | Q16602 | 4/20 | 0.43 |
| ▸ | XIAP | P98170 | 2/20 | 0.43 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 6/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | CASP2 | P42575 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12914540 | 0.83 | SLC6A2 (0.54) | CALCRLREN | |
| SCHEMBL646710 | 0.83 | SLC6A2 (0.54) | CALCRLREN | |
| SCHEMBL13079803 | 0.83 | ELANE (0.47) | GZMBXIAPELANERENACE | |
| SCHEMBL13951109 | 0.80 | XIAP (0.55) | XIAPMLXELANE | |
| SCHEMBL14209345 | 0.80 | XIAP (0.55) | XIAPMLXELANE | |
| SCHEMBL30657497 | 0.80 | CALCRL (0.44) | CALCRLELANERENCASP3CASP2 | |
| SCHEMBL14209504 | 0.78 | XIAP (0.47) | XIAPMLXELANE | |
| SCHEMBL13951211 | 0.78 | XIAP (0.47) | XIAPMLXELANE | |
| SCHEMBL13951115 | 0.78 | CASP1 (0.54) | ELANEACE | |
| SCHEMBL13928229 | 0.78 | CASP1 (0.54) | ELANEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772366-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | GZMB 2387/4885CALCRL 229/4885XIAP 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.